Nanologica

Board/Management Information • Oct 14, 2025

NANOLOGICA ANNOUNCES NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2026

In accordance with the current nomination committee instructions, the chairman of the board has contacted Nanologica's three largest shareholders or owner groups in terms of voting rights as of September 30, 2025, each of whom has been offered to appoint a representative to constitute the nomination committee of Nanologica AB for the 2026 Annual General Meeting.

The nomination committee for Nanologica AB's AGM 2026 thus consists of the following three members:

• Carl-Johan Spak (Flerie Invest AB)
• Niklas Sjöblom (Konstakademiens stiftelser)
• Kalle Olby (Vega Bianca AB)

The nomination committee together represents 53.0 percent of the votes and shares in Nanologica AB as of September 30, 2025.

The nomination committee's task is to present proposals for the 2026 AGM regarding the election of the chairman of the meeting, the number of board members to be elected by the meeting, election of the chairman of the board and other members of the board, board fees and any remuneration for committee work, election of auditors (if applicable) and auditors' fees, as well as proposals for the principles that shall apply to the composition and work of the nomination committee for the next AGM (if applicable).

The 2026 AGM is planned to be held in Stockholm on May 21, 2026. Shareholders who wish to submit proposals to Nanologica's nomination committee may do so by e-mail to valberedning@nanologica. com no later than January 31, 2026. The nomination committee's proposals will be presented in the notice convening the AGM and on the company's website.

For further information, please contact

Gisela Sitbon

Chairman of the board

Ph: +46 70 282 55 58 or e-mail: gisela@sitbon.nu

About Nanologica AB (publ)

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

NANOLOGICA ANNOUNCES NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2026